Modulator compounds of drug resistance in epithelial tumor cells
The described invention provides a method of treating a patient with an epithelial cancer comprising administering a composition comprising a therapeutic amount of an inhibitor of a BTK protein and one or more chemotherapeutic agent(s) selected from the group consisting of an antimetabolite, a platinum coordination compound, an alkylating agent and a combination thereof, wherein the composition is effective to reduce one or more of tumor cell growth, tumor cell clonogenicity, tumor cell proliferation, tumor cell viability and tumor volume and the therapeutic amount of the inhibitor of a BTK protein and the one or more chemotherapeutic agent(s) exerts a synergistic effect. The described invention also provides methods of treating a chemotherapy drug-resistant cancer and sensitizing a cancer patient to chemotherapy.
1. A method of treating a chemotherapy drug-resistant cancer being characterized by increased levels of BTK expression relative to a peritumoral tissue control, comprising administering a therapeutic amount of a small molecule inhibitor of a BTK protein, wherein the therapeutic amount is effective to induce cell death.
2. The method according to claim 1 , wherein the small molecule inhibitor is selected from the group consisting of AVL-292, (2Z)-2-cyan-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide (LFM-A13), siRNA silencing a BTK gene, ibrutinib and dasatinib.
3. The method according to claim 1 , wherein the drug-resistant cancer is an epithelial cancer.
4. The method according to claim 3 , where the epithelial cancer has a mutated or deleted p53 gene.
5. The method according to claim 3 , wherein the epithelial cancer is selected from the group consisting of colon cancer, lung cancer, breast cancer, ovarian cancer, pancreatic cancer, and stomach cancer.
6. The method according to claim 5 , wherein the epithelial cancer is colon cancer.
7. The method according to claim 1 , wherein the BTK protein is of the sequence shown in SEQ ID NO: 2.